Oriola-KD acquired the minority holding of Pfizer in Kronans Droghandel AB

Oriola-KD Corporation Stock Exchange Release 31 August 2006 at 10.30 a.m.

Oriola-KD Corporation has increased today its holding in Kronans Droghandel AB
(KD) in Sweden from 69.39 per cent to 82.96 per cent after acquiring the
minority holdings of Pfizer AB and Pfizer Health AB in KD. Pfizer's holding in
KD was 13.57 per cent (Pfizer AB 12.51 per cent and Pfizer Health AB 1.06 per
cent). 

The share purchase was paid in cash. Oriola-KD and Pfizer have agreed not to
publish the purchase prices of shares. The acquisition in question cannot be
deemed significant in accordance with the Rules of the Helsinki Stock Exchange. 

The representatives of Pfizer in the Board of Directors of KD, Niklas Prager
(member) and Nikolaj Sörensen (deputy member), will resign from the Board of
Directors of KD today. 

The minority shareholdings after the transactions of shares in KD are divided
as follows: Merck Sharp & Dohme Sverige AB 12.51 per cent, Astra Arcus AB 2.66
per cent and Organon AB 1.87 per cent. 

Oriola-KD Corporation

Eero Hautaniemi       Henry Haarla
President and CEO     General Counsel

For additional information, contact:

Eero Hautaniemi
President and CEO
tel. +358 10 429 2109
email: eero.hautaniemi@oriola.com

Kimmo Virtanen
CFO
tel. +358 10 429 2069
email: kimmo.virtanen@oriola.com

Distribution
Helsinki Stock Exchange
Principal media

Published by:
Oriola-KD Corporation
Corporate Communications
Harmaaparrankuja 1
FI-02200 Espoo
www.oriola-kd.com